The Next Generation of Medicines
Excessive or uncontrolled inflammation is known to be the source of many chronic diseases and aging. Drawing on 30 years of research, Amytrx is harnessing the novel power of cell-penetrating anti-inflammatory peptide discoveries to advance new medicines aimed at the prevention and treatment of inflammatory diseases. Our lead therapeutic peptide AMTX-100 is bioengineered from human protein sequences that modulate the immune system by a selective, natural process already used by cells, reducing pathogenesis in a range of conditions. AMTX-100 can bind to and penetrate immune cells to attenuate their intracellular molecular machinery and help ease inflammation early in the process in advance of gene activation.
In clinical studies, AMTX-100 has been found to open a new frontier with the potential to overcome a range of chronic diseases caused by inflammation. AMTX-100’s patented delivery system boasts impressive safety, tolerance, and efficacy in both preclinical and recent and ongoing clinical studies.
AMTX-100 represents a new mechanistic approach to treatment with extensive evidence in animal models of human inflammatory diseases that supports an impressive pipeline with the potential to overcome a range of chronic inflammatory diseases. Our initial focus is in treating dermatologic conditions, starting with atopic dermatitis.
Building Collaborations and Partnerships
AMTX-100 sequences provide the basis for a broad therapeutic platform. Amytrx holds exclusive rights to an extensive portfolio of US and international patents. Our business strategy involves establishing collaborative opportunities that expand the use of this platform with pharmaceutical and biotechnology partners, as well as clinical and research organizations, to advance new or complementary therapies for chronic diseases where excessive inflammation or metabolic imbalances play key causative roles.
We welcome the opportunity to explore your research interests where AMTX-100 technology may provide therapeutic applications.